EGFR and non-small cell lung carcinoma: In addition, in a study that demonstrated a 30% objective response to gefitinib as a first-line treatment for NSCLC, the EGFR gene status could be examined using cytology specimens in only 13 of 40 (32.5%) patients (Niho et al, 2006).